Biotechnology
NeoPlex (TM) HPV29 Detection, a new molecular detection kit from Genematrix, acquires European CE-IVD certification
* Real-time PCR-based human papillomavirus (HPV) detection product is launched. * Simultaneous HPV detection and genotyping of 29 HPV types are available. PANGYO,South Korea, Oct. 12, 2021 /PRNewswire/ -- Genematrix (KRX 109820), specialized in real-time PCR based molecular diagnostics, annou...
ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an Expanded Therapeutic Window at the AACR-NCI-EORTC International Conference
WOODINVILLE, Wash. and SUZHOU, China, Oct. 7, 2021 /PRNewswire/ -- ProfoundBio announces that preclinical data from its novel, proprietary ADC technology platform are being presented at the 2021 Molecular Targets and Cancer Therapeutics conference hosted by the American Association for Cancer Res...
Amplo Biotechnology Closes Series Seed Financing to Advance Gene Therapies for The Treatment of Neuromuscular Junction Disorders
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- Amplo Biotechnology, a privately held US-based biotech focused on developing AAV (Adeno-associated Virus)-based gene therapies for diseases affecting the neuromuscular junction, today announced the successful closing of an undisclosed Series Seed financing. ...
I-Mab Announces Upcoming Participation at October Conferences
SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October...
Binhai sets ambitious biomedical goals with support of key companies
TIANJIN, China, Sept. 30, 2021 /PRNewswire/ -- A news report by chinadaily.com.cn: The Binhai New Area in North China's port city of Tianjin has gathered together more than 1,500 biomedical companies that have made great scientific achievements in key areas, such as recombinant proteins and stem...
Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board
SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messager RNA (mRNA) platform company inSingapore aspiring to address various diseases with unmet medical needs for emerging markets through novel vaccines and therapeutics, today announced that one of the to...
I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab
* The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021The current U.S. NHL clinical trial has now expanded to include clinical sites inChina as an international multi-center clinical trial, which will potentially lead to a r...
GenFleet and Innovent Starts First-in-human Phase I/II Trial of KRAS G12C Inhibitor
GUANGZHOU, China, Sept. 29, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, and Innovent Biologics (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize...
Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards
WUHAN, China and SAN DIEGO, Sept. 27, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company seeking to improve lives through the curative potential of gene therapies, announced the opening of its state-of-the-art manufacturing facility at the Phase II Suz...
Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, the clinical trial of its anti-FcRn antibody, batoclimab (HBM9161), has completed the first dosing of first patient in registrational phase III trial f...
Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference
* Early Positive Phase 2 efficacy and safety data are both statistically significant and clinically meaningful. * No SAE related to Silmitasertib was reported. * Silmitasertib is a host-directed antiviral and an anti-inflammatory investigational therapy expected to be effective against eme...
Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002
SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it received IND clearance on...
GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target
NANJING, China, Sept. 26, 2021 /PRNewswire/ -- On September 26, 2021, GenScript ProBio and AskGene signed a license agreement forGenScript ProBio's single-domain antibody (sdAb) targeting an immune checkpoint target.GenScript ProBio grants a non-exclusive global license to AskGene to use GenScrip...
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote ...
New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA
HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...
The First US World-Class Bioscience Design Corporation Officially Launched
TAIPEI, Sept. 22, 2021 /PRNewswire/ -- TCI Co., Ltd. set up a subsidiary in the United States for the first time in 2019 to expand its business footprint and bring its successful experience inAsia to the United States. After two years of continuous effort, it has accumulated a series of extensiv...
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
* Trial enrolled over 30,000 adult & elderly participants across 4 continents; 100% of SARS-CoV-2 strains observed in efficacy analysis were variants (Delta was predominant strain) * Primary and secondary efficacy endpoints were successfully met * 100% efficacy against severe COVID-19 & hosp...
Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
INCHEON, South Korea, Sept. 22, 2021 /PRNewswire/ -- Samsung Biologics, a global contract development and manufacturing organization (CDMO), introduced its proprietary technology platform, S-CellerateTM, at the BioProcess International Conference (BPI 2021) to offer clients an integrated and seam...
Asieris Appoints Dr. Alice Chen as Vice President, Discovery Biology and Head of Translational Research
SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- Asieris Pharmaceuticals announced the appointment of Dr.Alice Chen as Vice President, Discovery Biology and Head of Translational Research with effect fromSeptember 20, 2021. She will report to Dr.Kevin Pan, Founder and CEO of Asieris. Alice has over 20 ...
New Therapy to Treat Advanced Small Cell Lung Cancer ZEPZELCA® (lurbinectedin) Approved in Singapore
Highlights: * ZEPZELCA® (lurbinectedin) is the first new therapy approved in Singapore to treat 2L metastatic small cell lung cancer (SCLC) in 20 years * ZEPZELCA provisional approval represents an important advance for adult patients whose metastatic SCLC has progressed on or after platinum-...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Multiple achievements made in China-Hungary BRI conference
[Picked up by 317 media titles]
2024-05-03 06:59Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 295 media titles]
2024-04-30 10:11Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 287 media titles]
2024-05-03 06:25TAILG Makes Grand Appearance at 2024 Asiabike Jakarta, Aiming to Set the Benchmark in Indonesia
[Picked up by 262 media titles]
2024-05-02 01:21